LONDON – Takeda Pharmaceutical Co. Ltd. is to acquire cell therapy specialist Tigenix NV in a deal valued at €520 million (US$626.7 million), giving the Japanese pharma full ownership of Alofisel, an off-the-shelf allogeneic therapy for anal fistulas that was recommended for European marketing approval in December.